Nuveen Asset Management Portfolio holdings
Nuveen Asset Management, founded in 1898 by John Nuveen and headquartered in Chicago, Illinois, is a leading global investment manager and subsidiary of TIAA, overseeing hundreds of billions in assets with a focus on fixed income, equities, and sustainable investing. Initially known for municipal bonds, Nuveen has expanded into a broad range of strategies, including mutual funds, ETFs, closed-end funds, and private capital solutions, serving institutional investors, financial advisors, and individuals. The firm emphasizes income-generating investments and ESG (environmental, social, governance) integration, leveraging its deep research capabilities and a century-long legacy in the bond market. With a strong presence in North America and growing international reach, Nuveen blends tradition with innovation to meet diverse client needs in the evolving investment landscape.
Top Buys
| 1 |
Apple
AAPL
|
$1.17B |
| 2 |
Valero Energy
VLO
|
$265M |
| 3 |
Advanced Micro Devices
AMD
|
$258M |
| 4 |
Progressive
PGR
|
$257M |
| 5 |
O'Reilly Automotive
ORLY
|
$236M |
Top Sells
| 1 |
NVIDIA
NVDA
|
$531M |
| 2 |
Meta Platforms (Facebook)
META
|
$483M |
| 3 |
Intel
INTC
|
$403M |
| 4 |
PXD
Pioneer Natural Resource Co.
PXD
|
$389M |
| 5 |
Merck
MRK
|
$341M |
Sector Composition
| 1 | Technology | 31.79% |
| 2 | Financials | 11.71% |
| 3 | Healthcare | 11.07% |
| 4 | Consumer Discretionary | 10.64% |
| 5 | Communication Services | 8.17% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
RGLS
3226
DELISTED
Regulus Therapeutics
RGLS
| $153K | ﹤0.01% |
+85,602
| New | +$153K |
|
|
GTHX
3227
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
| $153K | ﹤0.01% |
+66,928
| New | +$153K |
|
3228
Gambling.com
GAMB
$294M
| $152K | ﹤0.01% |
18,540
| – | – |
|
3229
1stdibs.com
DIBS
$100M
| $152K | ﹤0.01% |
+33,826
| New | +$152K |
|
3230
Kaltura
KLTR
$229M
| $151K | ﹤0.01% |
126,173
| – | – |
|
3231
Taboola.com
TBLA
$1,000M
| $151K | ﹤0.01% |
+43,855
| New | +$151K |
|
3232
Veru
VERU
$49.8M
| $150K | ﹤0.01% |
+17,856
| New | +$150K |
|
3233
Geospace Technologies
GEOS
$230M
| $150K | ﹤0.01% |
+16,684
| New | +$150K |
|
3234
Aemetis
AMTX
$152M
| $148K | ﹤0.01% |
+49,234
| New | +$148K |
|
3235
Lifecore Biomedical
LFCR
$283M
| $148K | ﹤0.01% |
+28,837
| New | +$148K |
|
3236
Eve Holding
EVEX
$1.18B
| $146K | ﹤0.01% |
36,010
| – | – |
|
3237
INmune Bio
INMB
$52.4M
| $146K | ﹤0.01% |
+16,518
| New | +$146K |
|
3238
Ultralife
ULBI
$119M
| $145K | ﹤0.01% |
+13,610
| New | +$145K |
|
3239
Consumer Portfolio Services
CPSS
$170M
| $143K | ﹤0.01% |
14,590
| – | – |
|
3240
Lifetime Brands
LCUT
$94.9M
| $143K | ﹤0.01% |
+16,644
| New | +$143K |
|
|
ENLC
3241
DELISTED
ENLINK MIDSTREAM, LLC
ENLC
| $142K | ﹤0.01% |
+10,311
| New | +$142K |
|
3242
LiveOne
LVO
$50.4M
| $141K | ﹤0.01% |
+89,692
| New | +$141K |
|
3243
Sky Harbour Group
SKYH
$338M
| $141K | ﹤0.01% |
+15,222
| New | +$141K |
|
3244
NL Industries
NL
$311M
| $140K | ﹤0.01% |
23,157
| – | – |
|
3245
Neuropace
NPCE
$323M
| $139K | ﹤0.01% |
+18,420
| New | +$139K |
|
3246
Caesarstone
CSTE
$48.7M
| $139K | ﹤0.01% |
+27,788
| New | +$139K |
|
3247
Acumen Pharmaceuticals
ABOS
$87.2M
| $137K | ﹤0.01% |
+56,664
| New | +$137K |
|
3248
Stereotaxis
STXS
$264M
| $135K | ﹤0.01% |
+73,990
| New | +$135K |
|
3249
Priority Technology Holdings
PRTH
$616M
| $133K | ﹤0.01% |
25,156
| – | – |
|
3250
374Water
SCWO
$59.1M
| $132K | ﹤0.01% |
109,748
| – | – |
|